ESR1 and cancer: The most pronounced differences between the cell lines included the induction of cell death (via the activation of caspase 7 and caspase 9 and PARP1 cleavage) and the inhibition of the estrogen response signaling pathway in the estrogen receptor-positive MCF7 cancer cell line.